Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.

ABSTRACT:

Purpose

Probing efficacy and safety of lusutrombopag in Chinese chronic liver disease (CLD) and severe thrombocytopenia (PLT < 50 × 10⁹/L) patients undergoing elective invasive procedures.

Methods

In this double-blind, parallel-group phase 3 study, 66 patients with CLD and severe thrombocytopenia were randomized 2:1 to lusutrombopag or placebo arm treatment regimens for seven days at 9 centers in China. Responders (PLT ≥ 50 × 10⁹/L that increased to ≥ 20 × 10⁹/L from the baseline and not received rescue therapy for bleeding) on Day 8 (the day after seven-day treatment) were assessed. PLT ≥ 50 × 10⁹/L on or after Day 8 and within 2 days before invasive procedure (alternative criteria for not requiring platelet transfusion) were also

SUBMITTER: Ding Z 

PROVIDER: S-EPMC9895009 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature